Showing 1681-1690 of 4063 results for "".
- Horizon Therapeutics Announces Phase 2 Trial Results Evaluating Dazodalibep for the Treatment of Sjögren’s Syndromehttps://modernod.com/news/horizon-therapeutics-announces-phase-2-trial-results-evaluating-dazodalibep-for-the-treatment-of-sjogrens-syndrome/2481357/Horizon Therapeutics announced that the primary endpoint was met for the second population in its phase 2 clinical trial evaluating dazodalibep for the treatment of Sjögren’s syndrome. The phase 2 trial evaluated two patient populations and positive results in the first patient po
- Bausch + Lomb Introduces Enhanced PreserVision AREDS 2 Formula Mini Soft Gels with OCUSorbhttps://modernod.com/news/bausch-lomb-introduces-enhanced-preservision-areds-2-formula-mini-soft-gels-with-ocusorb/2481335/Bausch + Lomb announced the US introduction of PreserVision AREDS 2 Formula mini soft gels with OCUSorb. This product is the only AREDS 2 eye vitamin with the OCUSorb formulation. Offering a proprietary composition of lutein and zeaxanthin, Bausch + Lomb said OCUSorb has
- Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol in Presbyopiahttps://modernod.com/news/ocuphire-pharma-announces-first-patient-enrolled-in-vega-2-pivotal-phase-3-trial-of-nyxol-in-presbyopia/2481333/Ocuphire Pharma announced the initiation of the VEGA-2 phase 3 pivotal trial with the first patient enrolled in late December. VEGA-2 is evaluating the efficacy and safety for two labels: Nyxol alone and Nyxol with adjunctive low-dose pilocarpine (LDP) therapy for presbyopia.
- Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet AMDhttps://modernod.com/news/adverum-biotechnologies-announces-first-subject-dosed-with-ixo-vec-in-the-phase-2-luna-trial-for-the-treatment-of-wet-amd/2481097/Adverum Biotechnologies announced that the first subject was dosed in the LUNA phase 2 trial evaluating ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) for the treatment of wet (AMD). “Dosing the first subject in the phase 2 LUNA study brings us a step cl
- Nanoscope Announces Completion of Enrollment in STARLIGHT Phase 2 Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Diseasehttps://modernod.com/news/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease/2481089/Nanoscope Therapeutics announced full enrollment of its phase 2 clinical trial of MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic monotherapy to restore vision in blind patients, for Stargardt disease. Six-month data from the phase 2 STARLIGHT trial are exp
- Genentech: New 2-Year Data Confirm Vabysmo Improves Vision With Fewer Treatments for Wet AMDhttps://modernod.com/news/genentech-new-two-year-data-confirm-vabysmo-improves-vision-with-fewer-treatments-for-people-with-wet-amd/2480965/Genentech announced new 2-year data from the TENAYA and LUCERNE studies that reinforce the long-term efficacy, safety and durability of Vabysmo (faricimab-svoa) in wet age-related macular degeneration (AMD). The 2-year data were presented at the 2022 American Society of Retina Specialis
- Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 TRANQUILITY‑2 Trial in Dry Eye Diseasehttps://modernod.com/news/aldeyra-therapeutics-achieves-primary-endpoint-in-phase-3-tranquility2-trial-in-dry-eye-disease/2480902/Aldeyra Therapeutics announced the achievement of the primary endpoint in the phase 3 TRANQUILITY-2 clinical trial (TRANQUILITY-2) of reproxalap, an investigational new drug candidate, for the treatment of dry eye disease. Reproxalap was statistically superior to vehicle for each of the two presp
- Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY-2 Trial in Patients with Dry Eye Diseasehttps://modernod.com/news/aldeyra-therapeutics-announces-completion-of-enrollment-in-phase-3-tranquility-2-trial-in-patients-with-dry-eye-disease/2480746/Aldeyra Therapeutics announced completion of enrollment in the phase 3 TRANQUILITY-2 trial of 0.25% reproxalap ophthalmic solution in patients with dry eye disease. The multicenter, double-masked, parallel-group TRANQUILITY-2 trial enrolled 361 patients randomized to receive either
- Regeneron Presents Encouraging Phase 2 Results for High-Dose Aflibercept 8 mg in Wet AMDhttps://modernod.com/news/regeneron-presents-encouraging-phase-2-results-for-high-dose-aflibercept-8-mg-in-wet-amd/2480636/Regeneron Pharmaceuticals announced results from its phase 2 proof-of-concept trial evaluating an investigational 8 mg high dose of aflibercept compared to the currently-approved 2 mg dose of Eylea (aflibercept) Injection in patients with wet age-related macular degeneration (AMD). The resul
- Novartis Announces Positive Year 2 Results of Phase 3 KESTREL Study of Beovu in Diabetic Macular Edemahttps://modernod.com/news/novartis-announces-positive-results-from-year-2-of-the-phase-3-trial-of-beovu-in-diabetic-macular-edema/2480504/Novartis announced the first interpretable results from year 2 (week 100) of the phase 3 KESTREL study. KESTREL assessed the safety and efficacy of Beovu (brolucizumab) 6 mg in patients with visual impairment due to diabetic macular edema (DME). Results from year 2 confirmed the visual acuit